Phase 1 Study of MPC-6827 and Temozolomide in Metastatic Melanoma
Status:
Completed
Trial end date:
2009-08-01
Target enrollment:
Participant gender:
Summary
This is an open-label, dose finding, multiple-dose study in subjects with metastatic
melanoma. Three dose levels of MPC-6827 will be administered with temozolomide to three
separate cohorts. Study endpoints will include determination of the maximum tolerated dose,
determination of dose limiting toxicities, and evaluation of evidence of anti-tumor activity
of MPC-6827 when given with temozolomide.